ReviewFrontiers in nutrition2024
Fenugreek derived diosgenin as an emerging source for diabetic therapy.
Review in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Fenugreek Is Superior to Guar Gum, Locust Bean Gum and Tara Gum for Metabolic Health: A Systematic Review.Nutrients · 2026Pooled it
- Efficacy and Tolerability of a Topical Peptide-Hyaluronic Acid Lip Treatment Using a Novel Delivery System in Subjects With and Without Prior Lip Augmentation.Journal of cosmetic dermatology · 2025Trial
- Agro-Industrial Potential of Yam (Foods (Basel, Switzerland) · 2026Review
- Combined Supplementation With Trigonella foenum-graecum and Nigella sativa Seed Powders Improves Glycemic Control, Dyslipidemia, and Organ Function in Alloxan-Induced Diabetic Rats.Journal of food science · 2026Article
- Harnessing Phytochemicals and Nanotechnology Synergy for Molecular, Epigenetic, and Microbiota-Driven Regulation in Type 2 Diabetes Mellitus.Pharmaceutics · 2026Review
- Diosgenin in polyendocrine metabolic ovarian syndrome: modulation of insulin resistance, inflammation, steroidogenesis, and metabolic dysfunction.Frontiers in endocrinology · 2026Review
- Bioactive Potential and Health Benefits ofFood science & nutrition · 2025Review
- Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Deciphering agronomic traits, biochemical components, and color in unique green-seeded fenugreek (Frontiers in nutrition · 2025Article
- An Updated Review of Molecular Mechanisms Implicated with the Anticancer Potential of Diosgenin and Its Nanoformulations.Drug design, development and therapy · 2025Review
- Characterization of bioactive compounds in fenugreek genotypes in varying environments: diosgenin, trigonelline, and 4-hydroxyisoleucine.Frontiers in plant science · 2025Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a chronic metabolic disease that endangers the entire body's tissues and organs. Diabetes impairs glucose and insulin regulation in the human body by causing pancreatic cell damage. Diabetes modifies pathways such as serine/threonine protein kinase (Akt) and Protein kinase C (PKC)/- glucose transporter 4 (GLUT4), peroxisome proliferator-activated receptor (PPAR) glucose absorption, and inhibits α-amylase and α-glucosidase, Sodium/glucose cotransporter 1 (SGLT-1), and Na
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.